Showing results (1991-2000 of 2,065) with videos related to

Sort By:
Pageof 207
Neurology|February 12, 2016
Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysisValeria A Sansone, James Burge, Michael P McDermott, et al.
BMC Cancer|August 19, 2021
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)Ho Wai Derrick Siu, Niall Tebbutt, Lorraine Chantrill, et al.
Thorax|October 15, 2021
Telerehabilitation for chronic respiratory disease: a randomised controlled equivalence trialNarelle S Cox, Christine F McDonald, Ajay Mahal, et al.
Cell Death & Disease|June 15, 2024
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancerOzge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, et al.
Hepatology Communications|August 29, 2025
Evidence that extracellular HSPB1 contributes to inflammation in alcohol-associated hepatitisAnne-Marie C Overstreet, McKenzie Burge, Annette Bellar, et al.
The European Respiratory Journal|May 8, 2024
European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illnessAnne E Holland, Anna Spathis, Kristoffer Marsaa, et al.
Scientific Reports|July 2, 2025
Investigating hepatic fibrosis heterogeneity by three-dimensional imaging in metabolic dysfunction-associated steatotic liver diseaseBuket Yigit, Ekin Ozgonul, Omer Yaman, et al.
Clinical Colorectal Cancer|January 8, 2025
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG)Matthew E Burge, David Espinoza, Katrin Marie Sjoquist, et al.
BMJ Open|September 6, 2017
Case management in primary care among frequent users of healthcare services with chronic conditions: protocol of a realist synthesisCatherine Hudon, Maud-Christine Chouinard, Kris Aubrey-Bassler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2018
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal CancerAndrew G Hill, Michael P Findlay, Matthew E Burge, et al.
Pageof 207